Baim Institute for Clinical Research

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...

The impact and evolution of environmental/occupational, behavioural, and metabolic risk factors on CVD burdens in the Asia–Pacific region from 1990 to 2023: a secondary analysis of the Global Burden of Disease Study 2023

Background Understanding epidemiological trends of the cardiovascular risk factors is integral in designing effective countermeasures in tackling cardiovascular diseases (CVD) in the Asia–Pacific. The study aims to examine the cardiovascular risk factor burden in the Asia–Pacific...

The role of biomarkers across the care continuum in acute heart failure

Acute heart failure (AHF) remains a global health challenge, characterized by high morbidity, mortality, and frequent rehospitalizations. The heterogeneity of clinical presentations in AHF and its complex underlying pathophysiology complicates diagnosis, risk stratification, and...